Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from JAVELIN Bladder 100 in subgroups defined by first-line chemotherapy regimen and analysis of overall survival from start of first-line chemotherapy

Srikala S. Sridhar,¹ Thomas Powles,² <u>Shilpa Gupta</u>,³ Miguel A. Climent Duran,⁴ Jeanny B. Aragon-Ching,⁵ Cora N. Sternberg,⁶ Paul Cislo,⁷ Nuno Costa,⁸ Alessandra di Pietro,⁹ Joaquim Bellmunt,¹⁰ Petros Grivas¹¹

¹Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; ²Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK; ³Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; ⁴Instituto Valenciano de Oncología, Valencia, Spain; ⁵Inova Schar Cancer Institute, Fairfax, VA, USA; ⁶Weill Cornell Medicine, Hematology/Oncology, Englander Institute for Precision Medicine, Meyer Cancer Center, New York, NY, USA; ⁷Pfizer, New York, NY, USA; ⁸Pfizer, Porto Salvo, Portugal; ⁹Pfizer srl, Milano, Italy; ¹⁰Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ¹¹University of Washington; Fred Hutchinson Cancer Center, Seattle, WA, USA

Presented at the AUA 2024 Annual Meeting, May 3-6, 2024; San Antonio, TX. Data originally presented at the 2023 ASCO Genitourinary Cancers Symposium, February 16-18, 2023; San Francisco, CA; Abstract No. 508.

Disclosures for Dr Gupta

- Consulting or advisory roles for AVEO, Gilead Sciences, Guardant Health, Loxo/Lilly, Merck & Co., Kenilworth, NJ, Pfizer, and the healthcare business of Merck KGaA, Darmstadt, Germany
- Speakers services for Bristol Myers Squibb, Gilead Sciences, Janssen Oncology, and Seagen
- Stock and other ownership interests in BioNTech, Moderna Therapeutics, and Nektar
- Research funding from Bristol Myers Squibb, Gilead Sciences, Merck & Co., Kenilworth, NJ, Moderna, Pfizer, QED Therapeutics, Roche, Seagen, and the healthcare business of Merck KGaA, Darmstadt, Germany

Background

- In the JAVELIN Bladder 100 trial, avelumab 1L maintenance + BSC significantly
 prolonged OS and PFS vs BSC alone in patients with advanced UC without PD following
 1L platinum-based chemotherapy^{1,2}
 - After ≥2 years of follow-up in all patients, median OS was 23.8 vs 15.0 months, respectively (HR, 0.76 [95% CI, 0.63-0.91]; p=0.0036)²
 - Long-term safety of avelumab 1L maintenance was demonstrated and no new safety concerns were identified²
- Results from this trial led to the approval of avelumab 1L maintenance in various countries worldwide
 - Avelumab 1L maintenance is recommended as a standard of care in international treatment guidelines for cisplatin-eligible and cisplatin-ineligible patients with advanced UC without PD after 1L platinum-based chemotherapy³⁻⁵


1L, first line; BSC, best supportive care; HR, hazard ratio; OS, overall survival; PD, progressive disease; PFS, progression-free survival; UC, urothelial carcinoma.

1. Powles T, et al. N Engl J Med. 2020;383(13):1218-30. 2. Powles T, et al. J Clin Oncol. 2023;41(19):3486-92. 3. NCCN Clinical Practice Guidelines: Bladder Cancer. V1.2024. 4. Powles T, et al. Ann Oncol. 2022;33(3):244-58; 5. Cathomas R, et al. Eur Urol. 2022;81(1):95-103.

Design of JAVELIN Bladder 100: an international phase 3 trial¹

Endpoints measured post randomization (after chemotherapy)

OS measured from the start of 1L chemotherapy



• Best response to 1L chemotherapy (CR or PR vs SD)

- Metastatic site when initiating 1L chemotherapy (visceral vs nonvisceral)
- We report post hoc analyses to evaluate:
 - OS from start of avelumab 1L maintenance in subgroups defined by 1L chemotherapy regimen
 - OS from the start of 1L chemotherapy

1L, first line; BSC, best supportive care; CR, complete response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; UC, urothelial carcinoma. *BSC (eg, antibiotics, nutritional support, hydration, and pain management) was administered per local practice based on patient needs and clinical judgment; other antitumor therapy was not permitted, but palliative local radiotherapy for isolated lesions was acceptable. [†]PD-L1+ status was defined as PD-L1 expression in ≥25% of tumor cells or in ≥25% or 100% of tumor-associated immune cells if the percentage of immune cells was >1% or ≤1%, respectively (Ventana SP263 assay). 1. Powles T, et al. N Enal J Med. 2020;383(13):1218-30.

Baseline characteristics by 1L chemotherapy regimen

	Cisplatin + gemcitabine		Carboplatin + gemcitabine	
	Avelumab + BSC (n=183)	BSC alone (n=206)	Avelumab + BSC (n=147)	BSC alone (n=122)
Age, median (range), years	66.0 (37.0-86.0)	67.0 (32.0-84.0)	71.0 (46.0-90.0)	73.5 (46.0-89.0)
ECOG PS, n (%) 0 1 ≥2	124 (67.8) 58 (31.7) 1 (0.5)	135 (65.5) 71 (34.5) 0	75 (51.0) 72 (49.0) 0	65 (53.3) 54 (44.3) 3 (2.5)
Site of metastasis*, n (%) Visceral Nonvisceral	103 (56.3) 80 (43.7)	121 (58.7) 85 (41.3)	80 (54.4) 67 (45.6)	59 (48.4) 63 (51.6)
PD-L1 status, n (%) [†] Positive Negative Unknown	101 (55.2) 69 (37.7) 13 (7.1)	98 (47.6) 74 (35.9) 34 (16.5)	74 (50.3) 65 (44.2) 8 (5.4)	54 (44.3) 53 (43.4) 15 (12.3)
Best response to 1L chemotherapy, n (%) CR or PR SD	132 (72.1) 51 (27.9)	149 (72.3) 57 (27.7)	107 (72.8) 40 (27.2)	82 (67.2) 40 (32.8)
CrCl, n (%) ≥60 mL/min < <mark>60 mL/min</mark> Unknown	118 (64.5) 65 (35.5) 0	132 (64.1) 69 (33.5) 5 (2.4)	53 (36.1) 93 (63.3) 1 (0.7)	54 (44.3) 67 (54.9) 1 (0.8)

• Patients in the carboplatin subgroup were older and included a larger proportion with ECOG PS ≥1 or CrCl <60 mL/min

Data of note in these subgroups are highlighted.


1L, first line; BSC, best supportive care; CR, complete response; CrCI, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; PR, partial response; SD, stable disease. *Site of metastasis at the start of 1L chemotherapy.

[†]PD-L1+ status was defined as PD-L1 expression in ≥25% of tumor cells or in ≥25% or 100% of tumor-associated immune cells if the percentage of immune cells was >1% or ≤1%, respectively (Ventana SP263 assay).

OS measured from start of avelumab maintenance in subgroups defined by 1L chemotherapy regimen

Cisplatin + gemcitabine


Carboplatin + gemcitabine



- OS was longer with avelumab + BSC vs BSC alone in both subgroups
- Investigator-assessed PFS was also longer in the avelumab + BSC arm vs the BSC alone arm in both subgroups
 - Cisplatin + gemcitabine: 5.7 months (95% CI, 4.6-7.5) vs 2.0 months (95% CI, 1.9-3.6); HR, 0.56 (95% CI, 0.446-0.713)
 - Carboplatin + gemcitabine: 3.7 months (95% CI, 3.6-5.6) vs 2.0 months (95% CI, 1.9-3.0); HR, 0.48 (95% CI, 0.362-0.640)

BSC, best supportive care; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

Exploratory analysis of OS measured from the start of 1L chemotherapy in the overall population




 The JAVELIN Bladder 100 trial only enrolled patients without disease progression following 1L platinum-based chemotherapy (ie, patients with CR, PR, or SD)

1L, first line; BSC, best supportive care; CR, complete response; HR, hazard ratio; OS, overall survival; PR, partial response; SD, stable disease.

Exploratory analysis of OS measured from the start of 1L chemotherapy in subgroups defined by 1L chemotherapy regimen

Cisplatin + gemcitabine

Carboplatin + gemcitabine



- OS measured from start of 1L chemotherapy was longer with avelumab + BSC vs BSC alone irrespective of 1L chemotherapy regimen
 - The JAVELIN Bladder 100 trial only enrolled patients without disease progression following 1L platinum-based chemotherapy (ie, patients with CR, PR, or SD)

1L, first line; BSC, best supportive care; CR, complete response; HR, hazard ratio; OS, overall survival; PR, partial response; SD, stable disease.

Exploratory analysis of long-term safety in subgroups defined by 1L chemotherapy regimen

	Cisplatin + gemcitabine		Carboplatin + gemcitabine	
Events, n (%)	Avelumab + BSC	BSC alone	Avelumab + BSC	BSC alone
	(n=182)	(n=204)	(n=142)	(n=119)
AE of any grade	182 (100)	160 (78.4)	136 (95.8)	90 (75.6)
Grade ≥3 AE	92 (50.5)	51 (25.0)	82 (57.7)	34 (28.6)
TRAE of any grade	147 (80.8)	5 (2.5)	107 (75.4)	1 (0.8)
Grade ≥3 TRAE	30 (16.5)	0	32 (22.5)	0
Serious AE	47 (25.8)	36 (17.6)	51 (35.9)	31 (26.1)
Serious TRAE	15 (8.2)	<mark>0</mark>	15 (10.6)	<mark>0</mark>
AE leading to interruption of avelumab	80 (44.0)	N/A	69 (48.6)	N/A
AE leading to discontinuation	19 (10.4)	0	27 (19.0)	0
TRAE leading to discontinuation	16 (8.8)	0	21 (14.8)	0
AE leading to death	3 (1.6)	9 (4.4)	4 (2.8)	12 (10.1)
TRAE leading to death	1 (0.5)	0	1 (0.7)	0
IRR of any grade	41 (22.5)	0	27 (19.0)	0

• Long-term safety with avelumab was similar in subgroups that had received 1L cisplatin or carboplatin

Conclusions

- Long-term follow-up from the JAVELIN Bladder 100 trial (median follow-up, ≥38.0 months) confirmed that avelumab 1L maintenance provided similar OS and PFS benefits in patients treated with prior 1L cisplatin- or carboplatin-based chemotherapy
 - The JAVELIN Bladder 100 trial only enrolled patients without disease progression following 1L platinum-based chemotherapy (ie, patients with CR, PR, or SD)
- In the overall population, median OS from the start of 1L platinum-based chemotherapy (exploratory analysis) was 29.7 months
- Long-term safety of avelumab 1L maintenance was similar in patients who had received 1L cisplatin- or carboplatin-based chemotherapy
- These results further support avelumab 1L maintenance as the standard of care in patients with advanced UC without PD following 1L platinum-based chemotherapy

Acknowledgments

- The authors thank the patients and their families, investigators, co-investigators, and the study teams at each of the participating centers
- This trial was sponsored by Pfizer and was previously conducted under an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945) and Pfizer
- Medical writing support was provided by Jamie Ratcliffe of Nucleus Global and was funded by EMD Serono (CrossRef Funder ID: 10.13039/100009945)



GET PRESENTATION PDF

Copies of this presentation obtained through this quick response (QR) code are for personal use only and may not be reproduced without permission from AUA and the authors



GET PLAIN LANGUAGE SUMMARY

Please scan this QR code with your smartphone app to view a plain language summary of the accepted scientific abstract